AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for ...

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology segment. Following the loss of exclusivity (LoE) for its flagship drug, ...

Feb 4 (Reuters) - ‌AbbVie forecast 2026 profit above Wall ‌Street estimates on Wednesday after the drugmaker posted a fourth-quarter results beat driven primarily by better-than-expected sales of its ...

Oct 25 (Reuters) - AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more ...

Robert Michael, CEO & Chairman of the Board, reported "record net sales and exceeded our financial commitments, advanced our pipeline across all stages of development and acquired new sources of ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

AbbVie has successfully navigated the post-patent-cliff sales erosion of its best-selling medicine. It can now return to revenue growth at a moderate pace -- or perhaps even a bit faster. Here's how ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth outlook ...